LBS SRL
LBS reported total assets of 291,800 € at the end of the 2025 financial year (annual accounts filed with the NBB on 29 May 2026).
The score of LBS shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +26 % Total assets -21 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
LBS's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 42,051 € | ||||
| Equity | 60,651 € | ||||
| Cash | 39,017 € | ||||
| EBITDA | 95,739 € | ||||
| Total assets | 291,800 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 29 May 2026
- Year ended 31 Dec 2024filed on 05 Jul 2025
- Year ended 31 Dec 2023filed on 02 Jul 2024
- Year ended 31 Dec 2022filed on 08 Jul 2023
- Year ended 31 Dec 2021filed on 04 Jul 2022
LBS's financial analysis
- Solvency20.8%sector median: 47.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of LBS
LBS's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0561.780.151
- VAT number
- BE0561780151
- Peppol
- Registered · 0208:0561780151 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 04 Sep 2014
- Registered office
- 9000 Ghent
- Latest accounts
- 2025 · filed on 29 May 2026
- Activity
- Manufacture of medicaments (NACE 21201)
LBS (SRL) has been based in Ghent since 2014, active in: manufacture of medicaments. For 2025, it reports a net profit of 42,051 € and equity of 60,651 €; its revenue is not published. Its solvency stands at 20.8%, below the median of its sector (47.2%).
Companies similar to LBS
Companies in the same business, of comparable size and area, outside its group.
- Parc Elisabeth Pharma Manufacture of pharmaceutical preparations Ganshoren · balance sheet 296,304 €
- Mountvector Bio Manufacture of pharmaceutical preparations Ottignies-Louvain-la-Neuve · balance sheet 180,416 €
- Unda Manufacture of pharmaceutical preparations Aywaille · balance sheet 517,605 €
- 272BIO Manufacture of pharmaceutical preparations Ghent · balance sheet 709,601 €
- Phenix Property Manufacture of pharmaceutical preparations Hoogstraten · balance sheet €1.13m
- Pledge Therapeutics Manufacture of basic pharmaceutical products Leuven · balance sheet 229,854 €
- Eurandlab Manufacture of pharmaceutical preparations Charleroi · balance sheet 27,845 €
- Dr. Lins - Dr. Dubois Manufacture of basic pharmaceutical products Antwerp · balance sheet 699,515 €
Frequently asked questions about LBS
What is the revenue of LBS?
LBS files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of LBS?
In Belgium, the VAT number is the company number prefixed with BE: BE0561780151 for LBS, if the company is VAT-registered. Its company number (CBE) is 0561.780.151.
Where is the registered office of LBS?
According to the CBE register, the registered office of LBS is in 9000 Ghent.
What is the equity of LBS?
At the close of the 2025 financial year, the equity of LBS amounts to 60,651 €, a solvency of 20.8% of total assets.
Who manages LBS?
The register lists 1 active mandates at LBS. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of LBS
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →